A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS) (ATAMS)
This study has been terminated.
(Sponsor voluntarily decided to terminate trial due to increased MS disease activity in atacicept arms as compared to placebo during a routine IDMC review.)
First Posted: March 25, 2008
Last Update Posted: May 24, 2016
Information provided by (Responsible Party):